Vijaya Diagnostics IPO Subscription Day-3
Last Updated: 15th December 2022 - 03:40 am
The Rs.1,895 crore IPO of Vijaya Diagnostics consists entirely of an offer for sale. It got a tepid response at the end of Day-1 and not much changed at the end of Day-2. As per the combined bid details put out by the BSE, Vijaya Diagnostics IPO was subscribed 4.54X overall at the close of Day-3, with solid traction from QIB demand. The issue has closed for subscription on Friday, 03 September.
As of close of 03 September, out of the 250.27 lakh shares on offer, Vijaya Diagnostics saw bids for 1,136.44 lakh shares. This implies an overall subscription of 4.54X. The granular break-up of subscriptions is as under.
Vijaya Diagnostics IPO Subscription Day-3
Category |
Subscription Status |
Qualified Institutional (QIB) | 13.07 Times |
Non-Institutional (NII) | 1.32 Times |
Retail Individual | 1.09 Times |
Employee | 0.98 Times |
Total | 4.54 Times |
QIB Portion
The QIB portion saw 13.07X subscription with demand for 928.63 lakh shares against 71.08 lakh shares available; net of anchor placement. On 31 August, Vijaya Diagnostics did anchor placement of Rs.566 crore to QIB investors like Fidelity, Aberdeen, Abu Dhabi Investment Authority, Government Pension Fund, ICICI Pru MF, Nippon MF, SBI MF and Kotak Life.
HNI Portion
The HNI portion got subscribed just 1.32X (getting applications for 70.60 lakh shares against the quota of 53.31 lakh shares). Funded applications and corporate applications, managed to get the HNI portion fully subscribed.
Retail Individuals
The retail portion got subscribed 1.09X at the end of Day-3, showing relatively tepid retail appetite. Among retail investors; out of the 124.38 lakh shares on offer, valid bids were received for 135.75 lakh shares, of which bids for 108.81 lakh shares were at the cut-off price.
The IPO is priced in the band of (Rs.522-Rs.531) and has allocated a quota of 35% for retail and 50% for QIBs.
Also Read:
Trending on 5paisa
04
5paisa Research Team
Discover more of what matters to you.
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.